Vir Biotechnology, Inc. (VIR) experienced a significant pre-market surge of 51.68% following a series of positive announcements from the company.

The biopharmaceutical firm entered into a global strategic collaboration with Japan's Astellas Pharma to co-develop and co-commercialize VIR-5500, its investigational prostate cancer treatment. Under the agreement, Vir will receive $335 million in upfront and near-term payments and is eligible for up to an additional $1.37 billion in development, regulatory, and sales milestone payments, plus tiered double-digit royalties on sales outside the United States.

Simultaneously, the company reported positive updated Phase 1 clinical trial results for VIR-5500, showing a favorable safety profile with no dose-limiting toxicities and demonstrating dose-dependent anti-tumor activity. Furthermore, Vir's fourth-quarter financial results significantly exceeded analyst expectations, with revenue of $64.1 million beating estimates of $23.2 million.